ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.53
1.40%
US Tech 100
17,606.80
1.08%
S&P 500
5,180.74
1.03%
US Dollar vs CAD
1.36687
-0.17%
Bitcoin
63,299.32
-1.09%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) News

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:HCM
DateTimeSourceHeadlineSymbolCompany
04/26/202410:09AMAlliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
04/26/20247:30AMRNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
04/22/20243:30AMRNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
04/08/20243:30AMRNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
04/05/20243:30AMRNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
04/02/20244:32AMAlliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
04/02/20241:00AMRNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
03/28/20246:08AMAlliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
03/28/20242:00AMRNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
03/22/20245:09AMAlliance NewsAlliance NewsHutchmed begins registration stage for sovleplenib phase 2/3 trialLSE:HCMHutchmed (china) Limited
03/22/20242:16AMAlliance NewsAlliance News*CORRECT: Hutchmed China initiates registration for phase 3 trials of sovleplenibLSE:HCMHutchmed (china) Limited
03/22/20242:00AMRNS Non-RegulatoryHutchmed (China) Limited Initiation of Registration Stage of P2/3 TrialLSE:HCMHutchmed (china) Limited
03/14/20244:00AMRNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
03/05/20242:30AMRNS Regulatory NewsHutchmed (China) Limited Vesting of awards under the LTIPLSE:HCMHutchmed (china) Limited
02/28/202411:31AMAlliance NewsAlliance NewsEARNINGS: Hutchmed revenue surges, Craven House's loss widensLSE:HCMHutchmed (china) Limited
02/28/20246:45AMRNS Non-RegulatoryHutchmed (China) Limited Publication of Form 20-FLSE:HCMHutchmed (china) Limited
02/28/20245:30AMRNS Regulatory NewsHutchmed (China) Limited 2023 Full Year Results and Business UpdatesLSE:HCMHutchmed (china) Limited
02/07/20243:50AMAlliance NewsAlliance NewsHutchmed hails fruquintinib trial results for gastric cancer treatmentLSE:HCMHutchmed (china) Limited
02/07/20241:00AMRNS Non-RegulatoryHutchmed (China) Limited Presentation of Phase III Data on FruquintinibLSE:HCMHutchmed (china) Limited
02/02/20243:52AMAlliance NewsAlliance NewsHutchmed says Inmagene exercises option to licence drug candidatesLSE:HCMHutchmed (china) Limited
02/02/20242:37AMRNS Non-RegulatoryHutchmed (China) Limited Inmagene Exercises Option for Two Drug CandidatesLSE:HCMHutchmed (china) Limited
02/01/20242:30AMRNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2023 Final ResultsLSE:HCMHutchmed (china) Limited
01/30/20243:20AMAlliance NewsAlliance NewsHutchmed celebrates cancer drug approval in hometown of Hong KongLSE:HCMHutchmed (china) Limited
01/30/20241:12AMRNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Receives Marketing Approval in Hong KongLSE:HCMHutchmed (china) Limited
01/11/20244:17AMAlliance NewsAlliance NewsTOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureauLSE:HCMHutchmed (china) Limited
01/11/20241:00AMRNS Non-RegulatoryHutchmed (China) Limited Sovleplenib NDA Granted Priority Review in ChinaLSE:HCMHutchmed (china) Limited
12/29/20232:30AMUK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:HCMHutchmed (china) Limited
12/29/20232:30AMUK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:HCMHutchmed (china) Limited
12/21/20235:36AMAlliance NewsAlliance NewsIN BRIEF: Hutchmed China renews deals with "substantial" shareholdersLSE:HCMHutchmed (china) Limited
12/21/20234:00AMUK RegulatoryHutchmed (China) Limited Overseas Regulatory AnnouncementLSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

Your Recent History

USOTC
INKW
Greene Concepts (PK)
USOTC
MVNT
Movement Industries (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
SFLM
SFLMaven (PK)
USOTC
TGLO
TheGlobe com (PK)
USOTC
TSOI
Therapeutic Solutions (PK)
NASDAQ
MULN
Mullen Automotive
USOTC
MGON
Megola (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
ALYI
Alternet Systems (PK)
USOTC
AFFU
Affluence (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
ILST
International Star (PK)
USOTC
AHRO
Authentic (CE)
NASDAQ
AGBA
AGBA
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved